<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496690</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT nr 2010-024488-42</org_study_id>
    <secondary_id>N-20100097</secondary_id>
    <nct_id>NCT01496690</nct_id>
  </id_info>
  <brief_title>Pregablin for Anxiety-comorbidity in Patients With Schizophrenia</brief_title>
  <acronym>PACS</acronym>
  <official_title>Pregablin for Anxiety-comorbidity in Patients With Schizophrenia - a Double-blinded Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCP-unit at Aarhus University Hospital, Aarhus, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital Pharmcacy North Denmark Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PACS study aims to investigate the efficacy and tolerability of pregabalin for
      schizophrenic patients that suffer from comorbid anxiety.

      The study design is an 8 week flexible dosage, randomized placebo controlled.

      The study population is patients diagnosed with ICD-10 schizophrenia and age 18-65. Patients
      are recruited from outpatient clinics from entire Denmark.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale</measure>
    <time_frame>Baseline - 4 weeks treatment - 8 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UKU-Overall adverse effect scale</measure>
    <time_frame>Baseline - 4 weeks treatment - 8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Anxiety-comorbidity to Schizophrenia</condition>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.</description>
    <arm_group_label>pregabalin</arm_group_label>
    <other_name>Brand name: Lyrica(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin Placebo Capsules</intervention_name>
    <description>Parallel to Active Comparator</description>
    <arm_group_label>Pregabalin Placebo Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-65 years

          -  An ICD-10 schizophrenia diagnosis F20.0-20.3 or F20.9

          -  Stable dosage of psychotropic 4 weeks before inclusion

          -  Hamilton Anxiety Scale total score &gt; 15

          -  Positive and Negative Syndrome Scale for Schizophrenia total score &lt; 70

          -  The Calgary Depression Scale for Schizophrenia total score &lt; 10

          -  Fertile women: Contraception during the trial

          -  S-creatinin within normal reference range

          -  Signed informed consent and power of attorney

        Exclusion Criteria:

          -  Significant substance abuse

          -  QTc &gt; 480 milliseconds

          -  Severe dysregulated diabetes

          -  For women: Pregnancy or breast-feeding

          -  Confinement in accordance with the Danish Law of Psychiatry

          -  Concrete suicidally

          -  Known hypersensitivity or allergic reaction to the active ingredient of the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Schjerning, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital, Psychiatry</name>
      <address>
        <city>Aalborg</city>
        <zip>9220</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety-comorbidity to schizophrenia</keyword>
  <keyword>Double-blinded randomized placebo controlled trial</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

